METALLIC NANOPARTICLES AS THERAPEUTIC CANCER PROBES

金属纳米颗粒作为治疗性癌症探针

• 批准号: 7721540
• 负责人: CHARLES J. SMITH
• 金额: $ 0.04万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-02-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7721540
• 关键词: Affinity; Architecture; Attention; Blood Vessels; Cancerous; Cell Surface Receptors; Cells; Computer Retrieval of Information on Scientific Projects Database; Development; Disease; Dose; Drainage procedure; Drug Kinetics; Funding; Gold; Grant; Hybrids; Institution; Lymphatic; Malignant Neoplasms; Methods; Permeability; Porosity; Property; Radiation therapy; Radioactive; Radioactivity; Research; Research Personnel; Resources; Source; Therapeutic; United States National Institutes of Health; Vascularization; base; cancer therapy; dosimetry; extracellular; interest; nanomedicine; nanoparticle; nanoparticulate; neoplastic cell; size

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Metallic nanoparticles, because of their size, chem. and phys. properties, are particularly attractive as therapeutic probes in treating cancer. Central to any clin. advances in nanoparticulate based therapy will be to produce hybrid nanoparticles that can be targeted to vascular, extracellular or cell surface receptors. Development of hybrid nanoparticles that specifically target cancer vasculature has received considerable attention. Most cancers have leaky vasculature and the defective vascular architecture, created due to the rapid vascularization necessary to serve fast growing cancers, in combination with poor lymphatic drainage allows increased permeation and retention effects. The leaky vasculature, because of higher porosity and permeability, serve as natural high affinity targets to metallic nanoparticles. Another attractive approach toward the application of nanotechnol. to nanomedicine is the utility of nanoparticles that display inherent therapeutic properties. For example radioactive gold nanoparticles present attractive prospects in therapy of cancer. The radioactive properties of Au-198 (bmax = 0.96 MeV: t1/2 = 2.7 d) and Au-199 (bmax = 0.46 MeV; t1/2 = 3.14 d) make them ideal candidates for use in radiotherapeutic applications. In addn., they both have imageable gamma emissions for dosimetry and pharmacokinetic studies and Au-199 can be made carrier-free by indirect methods. Gold nanoparticles are of interest for treatment of disease as they can deliver agents directly into cells and cellular components with a higher concn. of radioactivity, e.g. higher dose of radioactivity, to cancerous tumor cells.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 金属纳米颗粒，由于其大小，化学。和物理。作为治疗癌症的治疗探针，特性特别有吸引力。 任何临床的中心。基于纳米核的治疗的进展将是产生可针对血管，细胞外或细胞表面受体的杂化纳米颗粒。 特别针对癌症脉管系统的混合纳米颗粒的发展受到了相当大的关注。 大多数癌症具有漏水的脉管系统和缺陷的血管结构，这是由于服务快速生长的癌症所需的快速血管化而产生的，结合淋巴引流不良，可以增加渗透和保留效应。 由于孔隙率和渗透性较高，漏水的脉管系统是对金属纳米颗粒的天然高亲和力靶标。 纳米技术应用的另一种有吸引力的方法。纳米医学是显示固有治疗特性的纳米颗粒的实用性。 例如，放射性金纳米颗粒在癌症治疗方面具有有吸引力的前景。 AU-198的放射性特性（BMAX = 0.96 MeV：T1/2 = 2.7 D）和AU-199（BMAX = 0.46 MEV; T1/2 = 3.14 D）使它们成为用于放射治疗应用中的理想候选者。 另外，它们都具有可成像的伽马排放剂进行剂量计和药代动力学研究，并且可以通过间接方法使载体不含载体。 金纳米颗粒可以治疗疾病，因为它们可以将药物直接输送到具有较高浓度的细胞和细胞成分中。放射性，例如更高剂量的放射性，对癌性肿瘤细胞。